Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
© 2024 Deng et al..
Diabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels, resulting in multi-organ dysfunction and various complications. Fusion proteins can form multifunctional complexes by combining the target proteins with partner proteins. It has significant advantages in improving the performance of the target proteins, extending their biological half-life, and enhancing patient drug compliance. Fusion protein-based drugs have emerged as promising new drugs in diabetes therapeutics. However, there has not been a systematic review of fusion protein-based drugs for diabetes therapeutics. Hence, we conducted a comprehensive review of published literature on diabetic fusion protein-based drugs for diabetes, with a primary focus on immunoglobulin G (IgG) fragment crystallizable (Fc) region, albumin, and transferrin (TF). This review aims to provide a reference for the subsequent development and clinical application of fusion protein-based drugs in diabetes therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Diabetes, metabolic syndrome and obesity : targets and therapy - 17(2024) vom: 23., Seite 343-362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deng, Wenying [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albumin |
|---|
| Anmerkungen: |
Date Revised 31.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/DMSO.S421527 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36778680X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36778680X | ||
| 003 | DE-627 | ||
| 005 | 20240131232154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/DMSO.S421527 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM36778680X | ||
| 035 | |a (NLM)38288338 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deng, Wenying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Deng et al. | ||
| 520 | |a Diabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels, resulting in multi-organ dysfunction and various complications. Fusion proteins can form multifunctional complexes by combining the target proteins with partner proteins. It has significant advantages in improving the performance of the target proteins, extending their biological half-life, and enhancing patient drug compliance. Fusion protein-based drugs have emerged as promising new drugs in diabetes therapeutics. However, there has not been a systematic review of fusion protein-based drugs for diabetes therapeutics. Hence, we conducted a comprehensive review of published literature on diabetic fusion protein-based drugs for diabetes, with a primary focus on immunoglobulin G (IgG) fragment crystallizable (Fc) region, albumin, and transferrin (TF). This review aims to provide a reference for the subsequent development and clinical application of fusion protein-based drugs in diabetes therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Fc protein | |
| 650 | 4 | |a albumin | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a fusion protein | |
| 650 | 4 | |a glucagon-like peptide 1 receptor agonists | |
| 650 | 4 | |a transferrin | |
| 700 | 1 | |a Zhao, Zeyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Kuang, Tongdong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, metabolic syndrome and obesity : targets and therapy |d 2008 |g 17(2024) vom: 23., Seite 343-362 |w (DE-627)NLM195025180 |x 1178-7007 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:23 |g pages:343-362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/DMSO.S421527 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 23 |h 343-362 | ||